Pharmacokinetic model-guided enoxaparin dosing in the Neonatal ICU: Retrospective cohort study to plan for prospective feasibility trial.

Traditional milligram per kilogram (mg/kg) dosing of enoxaparin in neonates frequently fails to achieve target anti-Xa levels promptly, necessitating repeated laboratory monitoring and dose adjustments. This study investigated whether a personalized dosing strategy based on predicted individual clearance and volume of distribution could improve outcomes, comparing standard-of-care (SOC) mg/kg dosing to pharmacokinetic (PK) model-informed precision dosing (MIPD). A retrospective analysis was conducted on hospitalized neonates treated with enoxaparin at less than 44 weeks postmenstrual age from 2019 to 2022.

Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.

Objective: To determine predictors and time to response to treatment with TNF-alpha blockers in patients with PsA in a longitudinal observational cohort.

Methods: We performed a cohort analysis of patients who were followed prospectively in a large PsA clinic. Response to treatment was defined as an improvement of at least 40% in active (tender and/or swollen) and swollen joint count (SJC) and 50% improvement in the Psoriasis Area and Severity Index (PASI) score.

Axial psoriatic arthritis: update on a longterm prospective study.

Objective: To evaluate changes in symptoms, spinal mobility, and radiographic features in patients with axial psoriatic arthritis (AxPsA).

Methods: Patients with AxPsA were identified from the University of Toronto Psoriatic Arthritis clinic database. Axial symptoms, metrology, and radiographic features at study entry were compared to 5-year and 10-year followup assessments.

Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort.

Objective: In a previous study in our clinic, methotrexate (MTX) conferred no advantage with respect to clinical response or progression of damage after 24 months in patients with psoriatic arthritis (PsA). Our aim was to determine if MTX is being used earlier in the course of PsA and in a higher dose and whether that has led to improved outcomes.

Methods: All patients treated with MTX for at least 24 months in our clinic, between 1994 and 2004, were included in the study.

Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis.

Objective: To correlate measures of spinal mobility used in the assessment of spondyloarthritis with radiographic severity, and to compare ankylosing spondylitis (AS) and psoriatic spondylitis (Ps-Sp) in this clinical-radiographic correlation.

Methods: As part of the International SPondyloarthritis Interobserver Reliability Exercise (INSPIRE) study, 20 spondyloarthropathy (SpA) experts met for an examination exercise assessing 19 patients with SpA -- 10 with Ps-Sp (9 men, mean age 52 yrs, mean disease duration 17 yrs) and 9 with AS (7 men, mean age 38 yrs, mean disease duration 16 yrs). Spearman correlation with bias correction was used to correlate median values of the spinal measurements obtained in the INSPIRE study with modified Stoke AS spinal score (mSASSS) and Bath AS Radiology Index-spine (BASRI-s) scores calculated by consensus of 2 assessors.

Improved survival in psoriatic arthritis with calendar time.

Objective: To determine whether there has been a change in mortality rates over the last 3 decades in patients with psoriatic arthritis (PsA) whose cases were followed prospectively.

Methods: Patients receiving followup care according to a standard protocol at the University of Toronto PsA Clinic between 1978 and 2004 were included. Information on patient deaths was collected prospectively.

A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?

Objective: To investigate whether there are differential effects of disease activity and damage on physical functioning as measured by the Health Assessment Questionnaire (HAQ) over the course of psoriatic arthritis (PsA).

Methods: Between June 1993 and March 2005, 382 patients attending the University of Toronto PsA clinic had completed > or =2 HAQs on an annual basis. At the time of each HAQ assessment, clinical and laboratory measures of disease activity and damage were recorded.

Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis.

Background: Fatigue is an important symptom in psoriatic arthritis (PsA).

Aim: To determine the reliability and validity of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale in PsA.

Methods: Consecutive patients attending the PsA clinic were assessed with the FACIT fatigue Scale twice, 1 week apart.

Predictors for radiological damage in psoriatic arthritis: results from a single centre.

Background: The predictors for the development of clinical damage in psoriatic arthritis (PsA) have been reported previously.

Aim: To identify predictors for radiological damage in PsA.

Methods: Patients followed-up prospectively according to a standard protocol at The University of Toronto between 1978 and 2004 were included.

Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases.

Objective: To assess clinical factors associated with disability and physical health in patients with systemic sclerosis (SSc) compared to psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) and healthy controls.

Methods: Eighty-two patients with SSc, 82 with PsA, 74 with SLE, 42 with RA, and 60 controls were recruited from various rheumatology clinics and underwent physical examination, tender point count, Health Assessment Questionnaire Disability Index (HAQ-DI) and Short Form-36 Health Survey (SF-36) assessments.

Results: SSc patients were younger and had shorter disease duration than the comparator groups.

Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity.

Objective: To identify processes that influence data collection, particularly in the reporting of deaths in mortality studies, using patient registry data.

Methods: The University of Toronto Psoriatic Arthritis Clinic has mechanisms for patient followup and identification of deaths. Logistic regression was used to identify patient characteristics that discriminate between 2 populations of deaths, those reported under regular followup and those reported in the context of special studies.

Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach.

Objective: To describe the longitudinal course of physical functioning in patients with psoriatic arthritis.

Methods: Between June 1993 and June 2003, 341 patients attending the University of Toronto Psoriatic Arthritis Clinic completed 2 or more Health Assessment Questionnaires (HAQs). At the time of administration of each HAQ, patients were assigned to 1 of 3 physical functional disability states, based on their HAQ score.

Clinical and radiological changes during psoriatic arthritis disease progression.

Objective: To determine the contribution of radiological findings at the initial visit with respect to classifying patients with psoriatic arthritis (PsA); and to determine the extent to which the clinical disease patterns change over time.

Methods: Patients with PsA were followed prospectively at 6-12 month intervals since 1978; 86 patients were registered within 1 year of diagnosis and were followed for at least 1 year. Based on the clinical information, including the actively inflamed joint count, damaged joint count, and the presence of back disease and arthritis mutilans, a clinical PsA pattern was assigned.